Otis W. Brawley, Director at Lyell Immunopharma, Inc. (LYEL), bought 35,640 shares at $0.56 ($20K) on 2025-03-31, disclosed to the SEC on 2025-04-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.